Last reviewed · How we verify
NCT05617378
Exploring the Risk Factors for Colorectal Cancer in Our General Population Using Asian Pacific Screening Score: a Survey From Pakistan
trial in Colorectal Cancer in 558 participants. Completed in 31 December 2023.
31 October 2023
Quick facts
| Lead sponsor | Sindh Institute of Urology and Transplantation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 558 |
| Start date | 1 November 2022 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Pakistan |
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Sponsor
Sindh Institute of Urology and Transplantation
Who can join
18 and older, any sex, with Colorectal Cancer or Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Pakistan, due to the lack of a National based cancer registry exact number of CRC cases is unknown. However, minimal data that is present in literature shows an increase in CRC cases with a concerning increase in incidence in younger age groups11. This makes it pertinent to understand current pattern of CRC and its risk factors from a local perspective. This will direct future strategies in an attempt to reduce the incidence and mortality associated with CRC in our general population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer.
Partyka O, Pajewska M, Czerw A, Deptała A, et al · · 2025 · cited 2× · PMID 39941735 · DOI 10.3390/cancers17030367
Verify or expand the search:
- PubMed search for NCT05617378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Sindh Institute of Urology and Transplantation trials
Trials by the same sponsor.
- NCT07510178 — Retrograde Intrarenal Surgery Versus Extracorporeal Shockwave Lithotripsy · NA · not yet recruiting
- NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
- NCT07493356 — Difficult Airway Prediction by Integrating STOP-BANG Criteria · recruiting
- NCT07510542 — Comparison of Stress Response Evoked by Conventional Versus Videolaryngoscope · NA · recruiting
- NCT07334548 — Post-Surgical Outcomes of Conventional vs 3-Point Mesh Fixation in Lichtenstein Repair: An RCT · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05617378 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sindh Institute of Urology and Transplantation
- Last refreshed: 22 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing